MedTrace Logo

CAREMM-2306: Advanced Immunotherapy vs. Classical Immunotherapy

NCT06202885 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 2500

Last updated 2024-01-12

No results posted yet for this study

Summary

The goal of this retrospective study is to compare between the case cohort and control cohort.

The case cohort consists of lymphoma patients treated with novel immunotherapy regimen including Chimeric antigen receptor T cell therapy, bispecfic antibody, and/or antibody-drug conjugate.

The control cohort consists of lymphoma patients who received conventional chemotherapy as standard-of-care

The main question\[s\] it aims to answer are:

* Survival times
* Response outcomes

Conditions

Interventions

DRUG

Immunotherapy

Immunotherapy

Sponsors & Collaborators

  • Seoul St. Mary's Hospital

    lead OTHER

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-10-01
Primary Completion
2025-12-31
Completion
2025-12-31

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06202885 on ClinicalTrials.gov